|Day Low/High||20.06 / 20.92|
|52 Wk Low/High||16.63 / 31.75|
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Kaleo's EpiPen compeitor the Auvi-Q was released today.
Prices look set to test key resistance, and this time should see a breakout to the upside.
Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Allergan raises the prices on nine drugs, but keeps the increases reasonable.
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
Mylan's EpiPen is going to start selling a generic version of its EpiPen allergy treatment with more than a 50% discount.
Mylan's much awaited generic version of its EpiPen treatment will be offered for sale next week, at a 50% discount.
Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.
The sector excelled right after the election, but lately has been sitting this rally out.
The Dow's winning streak continued with the index closing higher for the 18th time in 22 sessions and clinching a record settlement for the third day in a row.
The stock remains pointed down with few signs of encouragement for bulls.
Wall Street ran at two speeds with the Dow Jones Industrial Average setting a record high earlier in the day while the Nasdaq plummeted into the red.
As we all know, the stock market and the economy abhor uncertainty.
On Wednesday, November 9, investors will grapple with the aftermath of Tuesday's presidential election, while parsing various earnings reports.
Jim Cramer is keeping an eye on quarterly results from Mylan which are due to be released on Wednesday after the markets close.
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
For the week of November 7, all eyes will be on Tuesday's presidential election.
Thursday felt a lot like capitulation in this space. I was buying.
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.